Drug PotentialThe market is assigning negligible value to a drug that clearly exceeds Sotyktu’s benchmarks, indicating a potential undervaluation of Alumis.
Financial EfficiencyThe reduction in R&D and SG&A expenses indicates improved financial efficiency, which is expected to fund operations into 2027.
Pipeline OpportunitiesAlumis is not a 'one-asset story'—the pipeline behind envu is active, catalyst-rich, and overlooked, indicating potential growth opportunities.